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GYNECOLOGYMenstrual preconditioning for the prevention
of major obstetrical syndromes in polycystic
ovary syndrome
Ivo Brosens, MD; Giuseppe Benagiano, MDThe presence of multiple ovarian cysts, anovulation, and endometrial progesterone
resistance in the neonate seems remarkably similar to ovarian and endometrial features
of the polycystic ovary syndrome (PCOS) of adolescent and adult women. In fact, in the
absence of cyclic menstruations after menarche, the neonatal progesterone resistance is
likely to persist and adversely affect young women with PCOS at the time of pregnancy
after induction of ovulation, because any persisting defect in progesterone response can
interfere with the process of decidualization and trophoblast invasion. The primigravid
woman with PCOS therefore is likely to be at risk of defective deep placentation as
manifested by the increased risk of major obstetric syndromes. A recent, large epide-
miologic study has demonstrated that the risk of preeclampsia and preterm delivery is
elevated in the 13- to 15-year old group, although it does not persist in the 16- to 17-year
old group. It is proposed therefore that induction of ovulation in the infertile nulligravid
woman with PCOS should be preceded by a period of progesterone withdrawal bleedings
to achieve full endometrial progesterone response by the time of pregnancy. The cyclic
administration of clomiphene citrate for a period to be determined by vascular response
may be an appropriate tool to reduce the risk of major obstetric syndromes by menstrual
preconditioning.
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preeclampsia, preterm birth, progesterone resistancehe polycystic ovary syndromeT (PCOS) is among the most com-
mon female endocrine disorders, which
occurs in 4-18% of reproductive-age
women worldwide.1 The syndrome is a
complex metabolic and endocrine dis-
order that is associated with the presenceFrom Catholic University Leuven, Leuven
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tance, obesity, infertility, and obstetric
complications. As a consequence, it may
have signiﬁcant implications for the
long-term physical and reproductive
health of affected women. In view of the
heterogeneity of the syndrome and the
lack of understanding of its pathogenesis
and mechanisms of action, it is not sur-
prising that, even after 3 consensus
meetings, the criteria to diagnose PCOS
remain unsettled. Currently, PCOS is
diagnosed by the presence of 2 of the
following features: chronic oligo- or
anovulation, clinical or biochemical ev-
idence of androgen excess, and the
presence of polycystic ovaries on sono-
graphic examination.2
Generally, the belief is that, in most
cases of PCOS, infertility results from
the absence of ovulation; at the same
time, it has also been recognized that
anovulation may not be the only reason
for the failure to conceive.3 Indeed, thereOCTOBER 2015is evidence that infertility in womenwith
PCOS cannot be attributed to anov-
ulation only but also to endometrial
dysfunction. A recent endometrial
biopsy study by Lopes et al4 showed
that conventional doses of proges-
terone may not be enough to correct
PCOS-associated changes in the endo-
metrial histomorphologic condition and
the receptivity markers. It is a fact that,
despite the ability to correct ovulatory
disorders in PCOS, pregnancy rates
remain paradoxically low, and sponta-
neous pregnancy loss rates are high.5
Once a woman with PCOS has
conceived, her problems are not over
because she will be at a higher risk of
miscarriage, both after spontaneous or
assisted conception (ART).6 A recent
Cochrane-based data review7 on the use
of metformin (an oral antidiabetic drug
used to reduce insulin resistance) evi-
denced that (1) there is no conclusive
evidence that metformin treatment
before or during ART cycles improves
the live birth rates in women with PCOS
who undergo ovulation induction or
in vitro fertilization and (2) its use
increases clinical pregnancy rates and
decreases the risk of ovarian hyperstim-
ulation syndromes.
In this clinical opinion, we focus on a
new theory of the pathogenesis of major
obstetric complications that have been
associated with PCOS to improve our
understanding and potentially the man-
agement of these obstetric complications
in women who are affected by PCOS.
Methods
The literature was searched via Scopus
and PubMed for the following key words:
polycystic ovary syndrome, progesterone
resistance, and metformin in combi-
nation with endometrium, menstrual
preconditioning, pregnancy, trophoblast,
TABLE 1
Major obstetric syndrome in women with polycystic ovary syndrome
Syndrome Odds ratio 95% confidence interval
Pregnancy-induced hypertension 3.67 1.98e6.81
Preeclampsia 3.47 1.16e2.62
Preterm birth 1.75 1.16e2.62
Gestational diabetes mellitus 2.94 1.70e5.08
Perinatal death 3.07 1.03e9.21
Boomsma et al.8
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ajog.org Gynecology Clinical Opinionpreeclampsia, or preterm delivery. In
addition, the references were examined
in published papers on related topics.
Pregnancy complications in PCOS
Several studies have documented an
association between PCOS and major
obstetric complications, particularly
preeclampsia and preterm birth. A
metaanalysis of pregnancy outcomes in
women with PCOS demonstrated a
signiﬁcantly higher risk of the develop-
ment of gestational diabetes mellitus,
pregnancy-induced hypertension, pre-
eclampsia, and preterm birth (Table 1).8
An exhaustive review of the literature
that assessed pregnancy outcomes and
the effect of metformin treatment
among women with PCOS by Ghazeeri
et al9 concluded that the weight of
available evidence suggests that pregnant
women with PCOS are at increased risk
of the development of preterm birth and
hypertensive disorders of pregnancy,
with a prevalence of 6-15% for preterm
birth, 10-30% for gestational hyperten-
sion, and 8-15% for preeclampsia. The
authors concluded that metformin has
proved to be effective in improving
ovulation and pregnancy rates among
patients who receive fertility-enhancing
agents and supports its use among
anovulatory women with PCOS.
However, the continuation of metfor-
min throughout pregnancy remains
controversial.
A population-based cohort study of
the risk of adverse pregnancy outcomes
in women with PCOS found that, in
singleton births, PCOS was associated
strongly with preeclampsia (adjusted
odds ratio, 1.45; 95% conﬁdence interval
[CI], 1.24e1.69) and very preterm birth
(adjusted odds ratio, 2.21; 95% CI,
1.69e2.90).10 A systematic review that
involved 2544 patients with at least 2
features of the 2003 Rotterdam criteria
for PCOS11 and 89,848 patients without
PCOS conﬁrmed that women with
the syndrome had signiﬁcantly higher
rates of gestational diabetes mellitus,
pregnancy-induced hypertension, pre-
eclampsia, preterm delivery, and small-
for-gestational-age infants.12 A 4-fold
increase in the risk of pregnancy-
induced hypertension linked to arterialwall stiffness has also been observed in
these patients. The risk of preeclampsia,
which is the most severe of all compli-
cations, is also 4 times higher in those
who experience PCOS.13
A MEDLINE search on relevant trials
by Zheng et al14 found that, in pregnant
women with PCOS, the pooled odds
ratio was 0.32 (95% CI, 0.19e0.55) for
early pregnancy loss, 0.37 (95% CI,
0.25e0.56) for gestational diabetes
mellitus, 0.53 (95% CI, 0.30e0.95) for
preeclampsia, and 0.30 (95% CI,
0.13e0.68) for preterm delivery. The
authors concluded that metformin
therapy throughout pregnancy could
decrease pregnancy-related complica-
tions in pregnant women with PCOS
with no serious detrimental side-effects.
An epianalysis of 2 randomized,
controlled trials that included 313
women with PCOS who were 18-42
years old and who had singleton preg-
nancies performed by Vanky et al15
showed that the metformin-treated pa-
tients had fewer late miscarriages/pre-
term deliveries. At the same time, there
was no difference in the prevalence
of gestational diabetes mellitus and
preeclampsia between the metformin
and the placebo groups. The authors
suggested that further randomized
studies should be performed before ﬁrm
conclusions can be drawn.
Endometrial progesterone resistance
in PCOS
The concept of “progesterone resistance”
implies that, in certain individuals, there
is a decreased responsiveness of target
tissues to bioavailable progesterone.16 In
recent years, the concept has beenOCTOBER 2015 Aminvestigated particularly in women with
endometriosis.17 There is increasing ev-
idence that an impaired progesterone
response can be found in the endome-
trium of women with PCOS. Gregory
et al18 demonstrated that the expression
of the p160 steroid receptor coactivators,
which serve as transcriptional coac-
tivators for a number of nuclear and
nonnuclear receptors, is regulated in the
endometrium during the menstrual cy-
cle in normal fertile women but is
over-expressed in the endometrium of
women with PCOS. Cermik et al19
investigated the up-regulation of the
homeobox gene HOXA10 that is neces-
sary for the receptivity to embryo im-
plantation. In vitro ﬁndings and
endometrial biopsy specimens that
were obtained from women with
PCOS show that testosterone decreases
HOXA10-messenger RNA, which leads
to the conclusion that diminished uter-
ine HOXA10 expression may contribute
to the diminished reproduction poten-
tial of women with PCOS. A review of
endometrial aspects of the “window of
implantation” in womenwith PCOS that
focused mainly on adhesion molecules
suggested that endometrial receptivity
seems to be the major limiting factor for
the establishment of pregnancy.4
Savaris et al,20 who compared gene
expression between endometrial samples
of normal fertile control subjects and
women with PCOS, concluded that
existing differences in gene expression
provide evidence of progesterone resis-
tance in midsecretory PCOS endome-
trium, independent of clomiphene
citrate (CC). It can also explain differ-
ences that were observed in this group oferican Journal of Obstetrics& Gynecology 489
Clinical Opinion Gynecology ajog.orgwomen in phenotypes of hyperplasia,
cancer, and poor reproductive outcomes.
In an in vitro experiment, Kajihara et al21
investigated the effect of androgens on
the expression of genes that are involved
in oxidative stress resistance in decid-
ualized human endometrial stromal
cells. These cells that were isolated from
hysterectomy specimens were decid-
ualized with 8-bromo cyclic adenosine
monophosphate and progesterone in the
presence or absence of dihydrotestoster-
one at various concentrations. The au-
thors concluded that androgens might
play a critical role in the decidualization
process at the time of embryo implan-
tation and trophoblast invasion by pro-
moting resistance to oxidative stress.
Recently, in the endometrium of patients
with PCOS, Yan et al22 showed differ-
ences in FADD (a gene that plays a role in
cell proliferation, cycle regulation, and
development) and BCL-2 (a gene that
encodes a protein that blocks the
apoptotic death of some cells such as
lymphocytes) expression during the
window of implantation. They suggested
that the decrease in cell apoptosis during
the implantation window in patients
with PCOS may be 1 of the causes of
reduced endometrial receptivity.
Finally, a recent review of endometrial
progesterone resistance in women with
PCOS concluded that progesterone-
mediated signaling pathways of expres-




Throughout pregnancy, the fetus is
exposed to high plasma concentrations
of unbound estrogens and progesterone.
Progesterone in the fetal circulation rises
to reach much higher values than in the
maternal circulation because of the de-
hydrogenase activity of the endothelial
cells of the placental circulation.24 Ober
and Bernstein25 carefully investigated
neonatal ovaries and uteri in a series of
169 autopsies and observed that, in
newborn infants, ovaries are frequently
polycystic, but failed to show any sign of
ovulation or corpus luteum formation.
In the uteri, they described in detail the
response of the fetal endometrium to the490 American Journal of Obstetrics& Gynecologyhigh circulating progesterone levels and
classiﬁed this response as null (prolifer-
ative or inactive) in 68% of their cases,
partial or early response (subnuclear
vacuolization) in 27%, and full (decidu-
alization or menstrual-like shedding) in
only 5%. Thus, remarkably, at birthmost
neonates satisfy the current criteria for
the diagnosis of PCOS by the presence
of polycystic ovaries, anovulation, and
progesterone-resistant endometrium.26
It can be speculated that the type of
progesterone resistance that is present in
the endometrium at birth is likely to
persist until the onset of puberty when
endogenous estrogens begin to stimulate
endometrial cells.26,27 Although full
progesterone response with “neonatal
menstruation” has been linked to
pelvic endometriosis in premenarche
and adolescence,26,27 a persisting degree
of progesterone resistance of the endo-
metrium after menarche can be linked to
defective deep placentation and major
obstetric disorders, which include pre-




The concepts of “ontogenetic proges-
terone resistance” and of “menstrual
preconditioning” infer that the human
uterus may start out as a relatively
immature organ that acquires the
competence for deep placentation in
response to dynamic remodeling events
triggered by menstruations, miscarri-
age, or parturition.30 Menstrual pre-
conditioning implies that progesterone
withdrawal bleedings or menstruations
evolved in the human because of the
need to initiate decidualization in the
absence of pregnancy and protect uter-
ine tissues from the profound hyper-
inﬂammation and oxidative stress that
are associated with deep placentation.
It is conceivable that, in most young
girls, ontogenetic progesterone resis-
tance may persist until menarche and
that full progesterone-responsiveness is
achieved only gradually after the onset
of cyclic menstruations. Al-Sabbagh
et al31 conjectured that steroid hor-
mone responses in the endometrium are
likely to be much more dynamic andOCTOBER 2015complex than previously appreciated.
Progesterone resistance, as manifested
in conditions such as endometriosis, is
not only a consequence of perturbed
progesterone signal transduction caused
by chronic inﬂammation but also is
associated with long-lasting epigenetic
reprogramming of steroid hormone
responses in the endometrium and
beyond. In this context, it is assumed
that cyclic endometrial decidualization
followed by menstrual shedding is an
example of physiologic preconditioning
that prepares uterine tissue for the dra-
matic vascular remodeling that is asso-
ciated with deep placentation. Indeed,
deep placentation involves the rem-
odeling of the spiral arteries in the
placentation zone, which includes the
endometrial and, most critically, the
myometrial segments. It is well accepted
that the pathogenesis of late onset pre-
eclampsia in the primigravid woman is
linked with defective deep placentation,
which is deﬁned by a restricted remod-
eling of the myometrial segments of the
spiral arteries in the placental bed.32
Defective decidualization and
trophoblast invasion in PCOS
Decidualization is described as the
postovulatory process of endometrial
remodeling in preparation for preg-
nancy, which includes secretory trans-
formation of the uterine glands, inﬂux
of specialized uterine natural killer
cells, and vascular remodeling. A more
restricted deﬁnition of the decidual
process denotes the morphologic and
biochemical reprogramming of the
endometrial stromal compartment. This
differentiation process is dependent
entirely on the convergence of cyclic
adenosine monophosphate and proges-
terone signaling pathways that drives
integrated changes at both the tran-
scriptome and the proteome level.33
Decidualization of stromal cells pre-
cedes and regulates trophoblast invasion
to resist inﬂammatory and oxidative
insults and to dampen local maternal
immune responses. Jindal et al34 sug-
gested that the spectrum of maternal and
fetal complications that are associated
with PCOS may be related to impaired
trophoblast invasion in the placental bed.
TABLE 2
Comparison of preeclampsia and preterm delivery in polycystic ovary
syndrome and teenager groups
Variable
Polycystic ovary
syndromea 13-15 years oldb 16-17 years oldb
Preeclampsia 3.5 (1.9e6.2) 2.5 (1.1e5.8) 0.7 (0.5e1.0)
Preterm delivery 1.8 (1.2e2.7) 3.0 (1.6e5.7) 1.1 (0.9e1.5)
Data presented as odds ratio (95% confidence interval).
a Boomsma et al8; b Leppa¨lathi et al.40
Brosens. Menstrual preconditioning in polycystic ovary syndrome. Am J Obstet Gynecol 2015.
TABLE 3
Prospective trials of clomiphene citrate vs metformin
Authors Trial Medication Ovulation, % Recommendationa
Palomba et al43 PnRT MF þ CC vs CC 62.9 vs 67.0 Both first-line options
Moll et al44 RT MF þ CC vs CC 64 vs 72 Both effective; higher
incidence of side-effects
with MF
Legro et al3 RT CC vs MF 49 vs 29 CC superior to MF
MF þ CC 60.4
Zain et al45 RT CC vs MF 59 vs 23.7 CC the first-line treatment for
induction of ovulation
MF þ CC 68.1
CC, clomiphene citrate; MF, metformin; PnRT, prospective non-randomized trial; RT, randomized trial.
a As first choice for the induction of ovulation in women with anovulatory polycystic ovary syndrome.
Brosens. Menstrual preconditioning in polycystic ovary syndrome. Am J Obstet Gynecol 2015.
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used a bioinformatics approach and
found evidence for impaired endome-
trial maturation in early pregnancy in
women who subsequently experienced
preeclampsia. Palomba et al36 in an
experimental case-control study colle-
cted trophoblastic and decidual tissue
after pregnancy termination during the
week 12 of gestation in women with and
without PCOS. The rate of implantation
site vessels with endovascular tropho-
blast invasion and the extent of endo-
vascular trophoblast invasion were
signiﬁcantly lower in patients with
PCOS, compared with healthy non-
PCOS subjects.
In a macroscopic and microscopic
study, Palomba et al37 investigated the
placenta from women with PCOS,
excluding obese patients who achieved a
pregnancy after the use of ovulation in-
duction or ART. They showed that
placental weight, thickness, density, and
volume were signiﬁcantly inferior in
women with PCOS, compared with
those without PCOS. Also, the percent-
age of patients with placental lesions and
the mean number of these lesions were
higher in the PCOS group than in the
control group.
A third study by the same group
attempted a matched-control evaluation
of the type of phenotype of PCOS that is
associated with placentation disorder,
again excluding obese patients who ach-
ieved a pregnancy after the use of ovula-
tion induction or ART.38 They found that
placental weight, thickness, density, and
fetoplacental weight ratio were signiﬁ-
cantly different in the full-blown PCOS
and nonpolycystic ovary phenotypes vs
the ovulatory and nonhyperandrogenic
phenotypes. The incidence of macro-
scopic placental lesions was only signiﬁ-
cantly different between control subjects
and the full-blown and nonpolycystic
phenotypes. The overall incidence
of microscopic placental lesions was
signiﬁcantly different among PCOS
phenotypes and was signiﬁcantly higher
in the full-blown and nonpolycystic
phenotypes than in the ovulatory and
nonhyperandrogenic phenotypes.
A major limitation of these placental
studies is that (1) they are based on thebasal plate of the placenta, which repre-
sents the battleﬁeld between decidua and
trophoblast, and, as such, is rather a poor
area for assessing deep invasion, and
(2) biopsy specimens from the center of
the placenta may not be representative
for deep invasion because decreased in-
vasion is not observed in the central but
in the paracentral region.39
Menstrual preconditioning to improve
pregnancy outcome
As stated, preeclampsia and preterm
birth are major obstetric risks in women
with PCOS and are characterized by
defective deep placentation.39 It has been
shown that insufﬁcient or defective
maturation of endometrium and de-
cidual natural killer cells during the
secretory phase and early pregnancy
precede the development of preeclamp-
sia35; in addition, the defective or
restrictive trophoblast invasion of the
spiral arteries can be explained by theOCTOBER 2015 Amprogesterone resistance in women with
anovulatory PCOS.36,37 Therefore, it
seems plausible that, in young women
with PCOS, the presence of ontogenetic
progesterone resistance, combined with
the absence of menstrual precondition-
ing constitutes a risk factor for pre-
eclampsia and preterm delivery. A recent
large epidemiologic study demonstrated
that the risk of preeclampsia and preterm
delivery is high in 13- to 15-year-old
pregnant teenagers and is normalized in
the 16- to 17-year-old pregnant teen-
ager40 (Table 2). This is in agreement
with the gradual increase of ovulatory
cycles from 49% at 1 year to 86% at
5 years after the menarche.41 Therefore,
the high risk of preeclampsia and pre-
term birth in PCOS after induction of
ovulation in young subjects can be
explained by the absence of menstrual
preconditioning and the persistence of
ontogenetic progesterone resistance at
the time of ovulation induction.erican Journal of Obstetrics& Gynecology 491
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demonstrated the efﬁciency of CC in
comparison with metformin for the
induction of ovulation in oligo- or
anovulatory women (Table 3). Based on
the results of a randomized, double-blind
clinical trial, Moll et al44 proposed to use
CC as a primary method for the induc-
tion of ovulation rather than metformin
or to add metformin to CC. Zain et al45
conﬁrmed in an Asian randomized-
controlled study that CC is superior to
metformin in inducing ovulation in
anovulatory women with PCOS.
When deciding on the best method to
induce ovulatory cycles in young patients
with PCOS, several considerations are in
order. First, treatment with CC is rela-
tively safe, although it has been ques-
tioned whether its long-term use may
alter the risk of ovarian cancer. Some 20
years ago, Rossing et al,46 who evaluated
a cohort of 3837 women who had been
treated for infertility over an 11-year
period, found a relative risk of invasive
or borderline malignant ovarian tumors
of 2.3 (95% CI, 0.5e11.4). In a further
analysis, they found that the use of the
drug during 12 cycles was associated
with an increased risk of ovarian tumors
among both women with ovarian ab-
normalities and those without apparent
abnormalities (relative risk, 11.1; 95%
CI, 1.5e82.3). In contrast, taking CC for
<1 year did not lead to an increased risk.
Some 10 years later, another large
retrospective cohort study by Brinton
et al47 observed a rate ratio of 0.82 (95%
CI, 0.4e1.5) in ever users of CC.
This rate increased, although in a
nonsigniﬁcant way, with long follow-up;
after 15 years, it became 1.48 (95% CI,
0.7e3.2). Finally, a very recent study by
Bjørnholt et al48 analyzed data from a
cohort of 96,545 women with fertility
problems from all Danish fertility clinics
for the years 1963-2006. They found that
the overall risk for borderline ovarian
tumors was not associated with the use
of CC (relative risk, 0.96; 95% CI,
0.64e1.44).
Second, the aforementioned study by
Moll et al44 concluded that metformin
may be a relatively safe medication but
that it is associated with a high incidence
of side-effects. At the same time, recent492 American Journal of Obstetrics& Gynecologypreliminary studies have demonstrated
that metformin has the potential to
reduce the risk of adverse pregnancy
outcomes in women with PCOS.15,49
Third, the question arises how to best
monitor the use of CC or metformin to
induce ovulatory cycles in achieving full
maturation of progesterone response in
the spiral arteries before attempting
pregnancy. The most direct method at
present is the estimation of blood ﬂow in
the spiral arteries at their origin in the
myometrial junctional zone and in the
endometrium. Yang et al42 were the ﬁrst
group to use a modiﬁed color Doppler
technique to determine the outcome
of in vitro fertilization by measuring
endometrial blood ﬂow. Women with
adequate endometrial thickness, but a
small intraendometrial power Doppler
area, tended to have an unfavorable
reproductive outcome. For clinical ap-
plications, Malhotra et al50 recom-
mended to estimate by color Doppler
sonography the junctional zone vas-
cular response during the mid-luteal
phase of the induced ovulatory men-
strual cycle. In a prospective clinical
study, Kim et al51 demonstrated that
3-dimensionalepower Doppler ultra-
sound scanning was useful for the
evaluation of endometrial and sub-
endometrial neovascularization in int-
rauterine insemination cycle. A recent
prospective study conﬁrmed that the
presence of subendometrial-endometrial
blood ﬂow improved cycle outcome in
frozen-thawed embryo transfer cycles.52
The clinical studies suggest that
3-dimensionalepower Doppler ultra-
sound scanning can be used during
induced ovulatory cycles to monitor the
stage of progesterone response by the
presence and extent of subendometrial-
endometrial blood ﬂow.
Conclusion
In the human, menstruations or cyclic
progesterone withdrawal bleedings may
play a role in the preconditioning or
maturation of the endometrial proges-
terone response. Therefore, the hypoth-
esis has been formulated that the woman
with full blown anovulatory PCOS who
attempts a ﬁrst pregnancy in the absence
of preceding cyclic menstruations is likelyOCTOBER 2015to be exposed to ontogenetic endometrial
progesterone resistance with increased
risk of miscarriage, preeclampsia, and
preterm delivery.
It is suggested that a period of induced
cyclic progesteronewithdrawal bleedings
by CC, rather than metformin, may
mature the endometrial progesterone
response.
Therefore, it should be investigated by
prospective studies whether uterine pro-
gesterone response can be matured by a
period of cyclic menstruations before an
attempt of the induction of ovulation for
the treatment of infertility. -
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